Analysis of the factors contributing to residual weakness after sugammadex administration in pediatric patients under 2 years of age
Pediatric Anesthesia · 2024
DOI: 10.1111/pan.14773 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pediatric Anesthesia, 2024. Verfasst von Alexandra C Cates und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: gamma-Cyclodextrins, Neuromuscular Nondepolarizing Agents, Neuromuscular Blockade. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Background
Sugammadex reverses the neuromuscular blockade induced by rocuronium and vecuronium and is approved by the U.S. Food and Drug Administration for use in patients aged over 2 years. There is, however, a paucity of data regarding its dosing profile in infants and children younger than 2 years.
Aims
The aim of this study was to assess the risk of recurarization, or re‐paralysis, in children under 2 years of age to increase awareness on the importance of appropriate neuromuscular blocked monitoring and reversal.
Methods
All patients aged ≤24 months who underwent an operative procedure at a tertiary medical center between January 1, 2018, and December 31, 2021, and received both rocuronium for neuromuscular blockade and sugammadex for neuromuscular blockade reversal, were identified in the electronic medical record. Patients were excluded from analysis if they (1) received vecuronium, cisatracurium, atracurium, or succinylcholine for neuromuscular blockade, (2) received neostigmine for reversal, or (3) underwent more than one operation within 24 h. We performed a survival analysis of sugammadex redose using a Cox proportional hazards model.
Results
We reviewed 2923 records. Sugammadex was redosed in 123 (4.2%) cases. The median [IQR] time to redose was 7 [4–17] min, and the median [IQR] amount of redose administered was 2.74 [1.96–3.99] mg/kg. Increasing patient age ( p < .01) and weight ( p < .01) were associated with reduced hazard rate of sugammadex redose. For a patient of median weight, increasing age from 3 to 13 months was associated with a 53% risk reduction (HR: 0.47; 95% CI: 0.24–0.91). For a patient of median age, increasing weight from 4.7 to 9.2 kg was associated with 41% risk reduction (HR: 0.59; 95% CI: 0.32–1.07). We failed to detect any other associations.
Conclusions
In this single‐center, retrospective cohort study of pediatric surgery patients, there was an association between the hazard of sugammadex redose with both increased age and weight.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, USA.
- Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Anesthesiology & Perioperative Informatics Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Förderung
- NHLBI NIH HHS
- NCATS NIH HHS
Zitieren
APA
Cates, A. C., Freundlich, R. E., Clifton, J. C., & Lorinc, A. N. (2024). Analysis of the factors contributing to residual weakness after sugammadex administration in pediatric patients under 2 years of age. Pediatric Anesthesia. https://doi.org/10.1111/pan.14773
Vancouver
Cates AC, Freundlich RE, Clifton JC, Lorinc AN. Analysis of the factors contributing to residual weakness after sugammadex administration in pediatric patients under 2 years of age. Pediatric Anesthesia. 2024. doi:10.1111/pan.14773
BibTeX
@article{Cates2024,
author = {Cates, Alexandra C and Freundlich, Robert E and Clifton, Jacob C and Lorinc, Amanda N},
title = {Analysis of the factors contributing to residual weakness after sugammadex administration in pediatric patients under 2 years of age},
journal = {Pediatric Anesthesia},
year = {2024},
doi = {10.1111/pan.14773}
}
EUVIMED